Who will benefit more from maintenance therapy of metastatic colorectal cancer?
Metrics: PDF 520 views | HTML 1018 views | ?
Mingyi Zhou1, Lingyu Fu2 and Jingdong Zhang3
1Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang 110042, Liaoning Province, PR China
2Department of Clinical Epidemiology and Evidence Based Medicine, The First Hospital of China Medical University, Shenyang 110001, Liaoning Province, PR China
3Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang 110042, Liaoning Province, PR China
Jingdong Zhang, email: firstname.lastname@example.org
Keywords: metastatic colorectal cancer; maintenance treatment; complete or partial response; stable disease; network meta-analysis
Received: July 04, 2017 Accepted: October 28, 2017 Published: December 21, 2017
Whether there is a difference in the efficacy of maintenance treatment for metastatic colorectal cancer (mCRC) between patients who achieve complete response (CR)/partial response (PR) and those with stable disease (SD) after induction treatment is controversial. PubMed, Cochrane Systematic Reviews, the Cochrane Collaboration Central Register of Controlled Clinical Trials, ClinicalTrials.gov, and databases of conferences were queried to identify randomized controlled trials evaluating the efficacy of maintenance treatment for mCRC patients. The search included articles dated from the inception of these resources until June 20, 2017. We estimated hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS). Network meta-analysis was performed to compare the efficacy of four regimens as maintenance treatment. Three randomized controlled trials comprising 1,301 patients were included in this network meta-analysis. Patients who achieved CR/PR after induction therapy benefited more from maintenance treatment than patients who achieved SD (PFS: HR [CR/PR] 1.50, 95% CI 1.09–2.08, vs. HR [SD] 1.35, 95% CI 1.04–1.74; OS: HR [CR/PR] 1.04, 95% CI 0.94–1.15, vs. HR [SD] 1.03, 95% CI 0.99–1.07). The results of network meta-analysis suggested that chemotherapy alone and observation were inferior to chemotherapy plus bevacizumab as maintenance treatment. Patients with mCRC who achieve CR/PR after induction therapy might benefit more from maintenance treatment than those with SD. Chemotherapy plus bevacizumab was the most appropriate regimen for maintenance treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.